Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
April 12th, 2024
Close Date
October 4th, 2024
Award Ceiling
$500,000.00
Opportunity No.
PAR-24-203

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health is offering a grant opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)". This grant aims to support studies that investigate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. The studies can be conducted using animal, cell culture, and/or human tissue models. The proposed models or experimental readouts should incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. The grant provides funding for mechanistic studies that address various aspects, including the impact of COVID-19 on CNS pathology and cognitive outcomes in the presence of AD/ADRD pathology, the acceleration of AD/ADRD pathology and cognitive deficits by COVID-19 in prodromal models, and the predisposition of COVID-19 for AD/ADRD and its interaction with comorbid conditions and risk factors. The grant does not require cost sharing or matching and is open to various eligible applicants. The deadline for application submission is October 4, 2024. For more information and to apply, visit the following link: Neuropathological Interactions Between COVID-19 and ADRD Grant.

Description

This NOFO will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is already present (for example, in a model of AD/ADRD). - Mechanistic studies that address how COVID-19 accelerates AD/ADRD pathology and cognitive deficits in a prodromal model (early phase, pre-symptomatic). - Mechanistic studies that address how COVID-19 predisposes for AD/ADRD and/or interacts with relevant comorbid conditions and risk factors (cellular mechanisms that could potentially increase the risk for future AD/ADRD).

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)". This grant is in the category of Health and falls under the funding instrument type of Grant. The grant does not require cost sharing or matching. The opportunity is discretionary and falls under CFDA number 93.866. The purpose of this grant is to support investigations into the cellular and molecular mechanisms of how and why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes in dementias with multiple etiologies. The grant aims to identify the mechanisms of co-pathology cellular and molecular interactions across brain regions and time, as well as determine the events that lead to worse phenotypic outcomes. The investigations should focus on a minimum of two relevant co-pathologies, such as tau, alpha-synuclein, TDP-43, TMEM106B, and vascular, with optional risk factors and co-morbidities. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant has an award ceiling of $500,000. The closing date for applications is October 4, 2024, and the archive date is November 9, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)". This grant aims to support the development and validation of novel human cellular models that are clinically and/or pathophysiologically relevant to ADRD. These cellular models should capture the various pathologies and multiple cell types observed in ADRDs. The validation process should include internal, face, construct, and predictive validation to the extent possible. The goal of these models is to aid in therapy development and enhance our understanding of human disease mechanisms and predisposition to developing neurodegenerative dementias. The models should be novel, complex, and address existing gaps in currently available models. Multidisciplinary teams are highly encouraged, and leveraging existing NIH cell repository resources is also encouraged. The grant has a funding ceiling of $500,000 and does not require cost sharing or matching. The deadline for applications is October 21, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-032.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-032.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)". This grant aims to support the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). The goal is to de-risk subsequent translational research and accelerate the development of novel therapies for ADRD. The grant will provide support for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidates in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. The impact of the target modulation will be measured and cross-validated in different modalities across collaborating laboratories. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. The deadline for applications is November 8, 2024. For more information, please visit the [grant opportunity website](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-011.html).
Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)". This grant aims to support innovative strategies that target and manipulate brain cell subtypes affected by aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). The goal is to develop and utilize sophisticated tools to precisely target disease-relevant cell subtypes in aged and degenerating mammalian brains, and to monitor and manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animal models. The grant provides up to 2 years of support for pilot activities (R61 phase) and up to 3 years of support for implementation activities including hypothesis testing (R33 phase). Eligible applicants include various institutions and organizations. The deadline for applications is October 7, 2024. For more information, visit the [grant opportunity website](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html).